Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non–Small-Cell Lung Cancer and High PD-L1 Tumor Expression
In clinical trials, first-line treatment with pembrolizumab improved overall survival (OS) in patients with advanced non–small-cell lung cancer (NSCLC) with a programmed death ligand 1 (PD-L1) tumor proportion score of ≥ 50%. However, data on the efficacy of this treatment between clinical trials an...
Saved in:
Published in | Clinical lung cancer Vol. 21; no. 5; pp. e366 - e379 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.09.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | In clinical trials, first-line treatment with pembrolizumab improved overall survival (OS) in patients with advanced non–small-cell lung cancer (NSCLC) with a programmed death ligand 1 (PD-L1) tumor proportion score of ≥ 50%. However, data on the efficacy of this treatment between clinical trials and actual clinical practice are inconsistent.
Ninety-five patients with histologically diagnosed advanced or recurrent NSCLC and a PD-L1 tumor proportion score of ≥ 50% who received pembrolizumab as first-line treatment were consecutively enrolled onto this multicenter retrospective study from February 2017 to December 2018. Clinical data were collected from electronic medical records. We assessed the objective response rate, progression-free survival (PFS), OS, and immune-related adverse events (irAE), and determined their associations with clinical characteristics.
The objective response rate was 40.0%. The median PFS was 6.1 months, and OS did not reach the median. Multivariate analyses revealed that nonadenocarcinoma histology (hazard ratio, 1.78; 95% confidence interval, 1.05-3.03; P = .015) and ≥ 3 metastatic sites (hazard ratio, 3.97; 95% confidence interval, 1.97-8.01; P < .001) were independently correlated with poor PFS. Patients with irAE and patients without interstitial lung disease had significantly longer PFS (14.0 and 4.9 months, respectively; P = .011) than patients without irAE or patients with interstitial lung disease.
The outcome of patients receiving first-line pembrolizumab treatment was worse in those with nonadenocarcinoma and with a large number of metastatic sites. Patients with irAE and without interstitial lung disease had a more favorable outcome.
To clarify the real-world efficacy and safety of first-line pembrolizumab, we assessed 95 consecutive patients with programmed death ligand 1 strongly expressed non–small-cell lung cancer in a retrospective multicenter trial. Nonadenocarcinoma and a large number of metastatic sites correlated with poor progression-free survival (PFS). PFS and overall survival (OS) were longer in patients with pembrolizumab-related adverse events; however, PFS and OS were shorter in patients with interstitial lung disease. |
---|---|
AbstractList | BACKGROUNDIn clinical trials, first-line treatment with pembrolizumab improved overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC) with a programmed death ligand 1 (PD-L1) tumor proportion score of ≥ 50%. However, data on the efficacy of this treatment between clinical trials and actual clinical practice are inconsistent. PATIENTS AND METHODSNinety-five patients with histologically diagnosed advanced or recurrent NSCLC and a PD-L1 tumor proportion score of ≥ 50% who received pembrolizumab as first-line treatment were consecutively enrolled onto this multicenter retrospective study from February 2017 to December 2018. Clinical data were collected from electronic medical records. We assessed the objective response rate, progression-free survival (PFS), OS, and immune-related adverse events (irAE), and determined their associations with clinical characteristics. RESULTSThe objective response rate was 40.0%. The median PFS was 6.1 months, and OS did not reach the median. Multivariate analyses revealed that nonadenocarcinoma histology (hazard ratio, 1.78; 95% confidence interval, 1.05-3.03; P = .015) and ≥ 3 metastatic sites (hazard ratio, 3.97; 95% confidence interval, 1.97-8.01; P < .001) were independently correlated with poor PFS. Patients with irAE and patients without interstitial lung disease had significantly longer PFS (14.0 and 4.9 months, respectively; P = .011) than patients without irAE or patients with interstitial lung disease. CONCLUSIONThe outcome of patients receiving first-line pembrolizumab treatment was worse in those with nonadenocarcinoma and with a large number of metastatic sites. Patients with irAE and without interstitial lung disease had a more favorable outcome. In clinical trials, first-line treatment with pembrolizumab improved overall survival (OS) in patients with advanced non–small-cell lung cancer (NSCLC) with a programmed death ligand 1 (PD-L1) tumor proportion score of ≥ 50%. However, data on the efficacy of this treatment between clinical trials and actual clinical practice are inconsistent. Ninety-five patients with histologically diagnosed advanced or recurrent NSCLC and a PD-L1 tumor proportion score of ≥ 50% who received pembrolizumab as first-line treatment were consecutively enrolled onto this multicenter retrospective study from February 2017 to December 2018. Clinical data were collected from electronic medical records. We assessed the objective response rate, progression-free survival (PFS), OS, and immune-related adverse events (irAE), and determined their associations with clinical characteristics. The objective response rate was 40.0%. The median PFS was 6.1 months, and OS did not reach the median. Multivariate analyses revealed that nonadenocarcinoma histology (hazard ratio, 1.78; 95% confidence interval, 1.05-3.03; P = .015) and ≥ 3 metastatic sites (hazard ratio, 3.97; 95% confidence interval, 1.97-8.01; P < .001) were independently correlated with poor PFS. Patients with irAE and patients without interstitial lung disease had significantly longer PFS (14.0 and 4.9 months, respectively; P = .011) than patients without irAE or patients with interstitial lung disease. The outcome of patients receiving first-line pembrolizumab treatment was worse in those with nonadenocarcinoma and with a large number of metastatic sites. Patients with irAE and without interstitial lung disease had a more favorable outcome. To clarify the real-world efficacy and safety of first-line pembrolizumab, we assessed 95 consecutive patients with programmed death ligand 1 strongly expressed non–small-cell lung cancer in a retrospective multicenter trial. Nonadenocarcinoma and a large number of metastatic sites correlated with poor progression-free survival (PFS). PFS and overall survival (OS) were longer in patients with pembrolizumab-related adverse events; however, PFS and OS were shorter in patients with interstitial lung disease. In clinical trials, first-line treatment with pembrolizumab improved overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC) with a programmed death ligand 1 (PD-L1) tumor proportion score of ≥ 50%. However, data on the efficacy of this treatment between clinical trials and actual clinical practice are inconsistent. Ninety-five patients with histologically diagnosed advanced or recurrent NSCLC and a PD-L1 tumor proportion score of ≥ 50% who received pembrolizumab as first-line treatment were consecutively enrolled onto this multicenter retrospective study from February 2017 to December 2018. Clinical data were collected from electronic medical records. We assessed the objective response rate, progression-free survival (PFS), OS, and immune-related adverse events (irAE), and determined their associations with clinical characteristics. The objective response rate was 40.0%. The median PFS was 6.1 months, and OS did not reach the median. Multivariate analyses revealed that nonadenocarcinoma histology (hazard ratio, 1.78; 95% confidence interval, 1.05-3.03; P = .015) and ≥ 3 metastatic sites (hazard ratio, 3.97; 95% confidence interval, 1.97-8.01; P < .001) were independently correlated with poor PFS. Patients with irAE and patients without interstitial lung disease had significantly longer PFS (14.0 and 4.9 months, respectively; P = .011) than patients without irAE or patients with interstitial lung disease. The outcome of patients receiving first-line pembrolizumab treatment was worse in those with nonadenocarcinoma and with a large number of metastatic sites. Patients with irAE and without interstitial lung disease had a more favorable outcome. |
Author | Nishikawa, Shingo Nishi, Kouichi Shibata, Kazuhiko Kase, Kazumasa Yoneda, Taro Araya, Tomoyuki Kimura, Hideharu Shirasaki, Hiroki Sone, Takashi Tambo, Yuichi Kasahara, Kazuo |
Author_xml | – sequence: 1 givenname: Yuichi surname: Tambo fullname: Tambo, Yuichi email: yuichi.tambo@staff.kanazawa-u.ac.jp organization: Department of Respiratory Medicine, Kanazawa University, Kanazawa, Japan – sequence: 2 givenname: Takashi surname: Sone fullname: Sone, Takashi organization: Department of Respiratory Medicine, Kanazawa University, Kanazawa, Japan – sequence: 3 givenname: Kazuhiko orcidid: 0000-0002-4864-5970 surname: Shibata fullname: Shibata, Kazuhiko organization: Department of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka, Japan – sequence: 4 givenname: Kouichi surname: Nishi fullname: Nishi, Kouichi organization: Department of Respiratory Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, Japan – sequence: 5 givenname: Hiroki surname: Shirasaki fullname: Shirasaki, Hiroki organization: Department of Respiratory Medicine, Fukui-ken Saiseikai Hospital, Fukui, Japan – sequence: 6 givenname: Taro surname: Yoneda fullname: Yoneda, Taro organization: Department of Respiratory Medicine, Komatsu Municipal Hospital, Komatsu, Japan – sequence: 7 givenname: Tomoyuki surname: Araya fullname: Araya, Tomoyuki organization: Department of Respiratory Medicine, National Hospital Organization Kanazawa Medical Center, Kanazawa, Japan – sequence: 8 givenname: Kazumasa surname: Kase fullname: Kase, Kazumasa organization: Department of Internal Medicine, Keiju Medical Center, Nanao, Japan – sequence: 9 givenname: Shingo surname: Nishikawa fullname: Nishikawa, Shingo organization: Department of Respiratory Medicine, Kanazawa University, Kanazawa, Japan – sequence: 10 givenname: Hideharu surname: Kimura fullname: Kimura, Hideharu organization: Department of Respiratory Medicine, Kanazawa University, Kanazawa, Japan – sequence: 11 givenname: Kazuo surname: Kasahara fullname: Kasahara, Kazuo organization: Department of Respiratory Medicine, Kanazawa University, Kanazawa, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32199806$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU1uFDEQhS0URH7gAiyQl2y6sd2_lthEw4QgtWAUgrK03HY58chtD3Z3RFhxh9yQk-DRBJasXJK_91T13ik68sEDQq8pKSmh7bttqZxTJSOMlISVhHbP0AnlVV-QlpOjPDesKbqK1MfoNKUtIaytKHuBjitGOe9Je4Ier0C64iZEp_HaGKukesDB4Asb01wM1gPewDTG4OzPZZIjth5v5GzBzwnf2PkOn-t76RVoHCK-ArXEmP_w5-B__3r8OknnihU4h4fF3-LVnoxYeo0v7e0d3nwoBoqvlylr1z92EVKywb9Ez410CV49vWfo28X6enVZDF8-flqdD4Wq-3ouamL42EkOjHCtKaV1Y6DvoW4oA101dUc5bSoA2RnWcs25aRWtR-CGcjWS6gy9PfjuYvi-QJrFZJPKy0oPYUmCVT3t65b2NKPsgKoYUopgxC7aScYHQYnYlyG2Yl-G2JchCBO5jCx68-S_jBPof5K_6Wfg_QGAfOW9hSiSysnmMG0ENQsd7P_8_wDNNZ25 |
CitedBy_id | crossref_primary_10_1016_j_cllc_2022_03_008 crossref_primary_10_3389_fonc_2023_1207295 crossref_primary_10_1007_s00508_021_01940_w crossref_primary_10_1097_MNM_0000000000001737 crossref_primary_10_1016_j_cllc_2020_06_010 crossref_primary_10_1111_1759_7714_13915 crossref_primary_10_3389_fonc_2021_618570 crossref_primary_10_1016_j_lungcan_2021_03_015 crossref_primary_10_1038_s41598_021_85696_3 crossref_primary_10_1016_j_lungcan_2021_06_004 crossref_primary_10_3389_fonc_2023_1044327 crossref_primary_10_3389_fphar_2023_1190001 crossref_primary_10_1016_j_jval_2022_10_012 crossref_primary_10_3390_cancers14122846 crossref_primary_10_1007_s12149_021_01694_5 crossref_primary_10_1016_j_esmoop_2022_100445 crossref_primary_10_3390_biology10090890 crossref_primary_10_1016_j_jtocrr_2022_100397 crossref_primary_10_3390_medicina57060547 crossref_primary_10_3390_cancers16101802 crossref_primary_10_15369_sujms_34_64 crossref_primary_10_2217_imt_2020_0280 crossref_primary_10_1016_j_rmcr_2021_101469 crossref_primary_10_4103_jcrt_jcrt_1660_21 crossref_primary_10_1111_1759_7714_13720 |
Cites_doi | 10.1097/PAI.0000000000000408 10.1200/JCO.18.00149 10.1001/jamaoncol.2017.2925 10.1056/NEJMoa1716948 10.1016/j.lungcan.2017.11.019 10.1056/NEJMoa1507643 10.1038/nrc3239 10.1146/annurev.immunol.23.021704.115611 10.1016/S0140-6736(15)01281-7 10.1016/j.jtho.2017.08.022 10.1056/NEJMoa1606774 10.1016/S0140-6736(16)32517-X 10.1634/theoncologist.2018-0563 10.1056/NEJMoa1801005 10.1038/nm730 10.1073/pnas.192461099 10.1016/j.cllc.2018.09.005 10.1084/jem.192.7.1027 10.1111/j.1600-065X.2010.00923.x 10.1056/NEJMoa1810865 10.1056/NEJMoa1504627 10.1038/nature22079 10.1016/j.ejca.2008.10.026 |
ContentType | Journal Article |
Copyright | 2020 Elsevier Inc. Copyright © 2020 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2020 Elsevier Inc. – notice: Copyright © 2020 Elsevier Inc. All rights reserved. |
DBID | NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.cllc.2020.02.017 |
DatabaseName | PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1938-0690 |
EndPage | e379 |
ExternalDocumentID | 10_1016_j_cllc_2020_02_017 32199806 S1525730420300425 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .FO .XZ .~1 0R~ 1P~ 1~. 29B 4.4 457 4G. 53G 5GY 5VS 6J9 6PF 7-5 8P~ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXUO ABBQC ABFNM ABJNI ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEGXH AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CAG COF DU5 EBS EFJIC EFLBG EJD EMB EMOBN F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM LCYCR M41 MET MO0 O-L O9- OAUVE OBH OC~ OHH OO- OVD P-8 P-9 PC. Q38 R2- ROL SDF SEL SES SPCBC SSH SSZ SV3 T5K TEORI UDS Z5R ~G- AAXKI AFJKZ AKRWK NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c484t-40f9b7a9e209dd11145fe88e4512ed354719153eea7f269d99f6c14be9f19cb03 |
IEDL.DBID | AIKHN |
ISSN | 1525-7304 |
IngestDate | Fri Aug 16 14:46:12 EDT 2024 Thu Sep 26 18:13:26 EDT 2024 Sat Sep 28 08:24:51 EDT 2024 Fri Feb 23 02:49:29 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Immune-related adverse events Immune checkpoint inhibitor Tumor proportion score of more than 50 First-line pembrolizumab Real-world data |
Language | English |
License | Copyright © 2020 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c484t-40f9b7a9e209dd11145fe88e4512ed354719153eea7f269d99f6c14be9f19cb03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-4864-5970 |
OpenAccessLink | http://hdl.handle.net/2297/00064734 |
PMID | 32199806 |
PQID | 2381846181 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_2381846181 crossref_primary_10_1016_j_cllc_2020_02_017 pubmed_primary_32199806 elsevier_sciencedirect_doi_10_1016_j_cllc_2020_02_017 |
PublicationCentury | 2000 |
PublicationDate | 2020-09-01 |
PublicationDateYYYYMMDD | 2020-09-01 |
PublicationDate_xml | – month: 09 year: 2020 text: 2020-09-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical lung cancer |
PublicationTitleAlternate | Clin Lung Cancer |
PublicationYear | 2020 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Mok, Wu, Kudaba (bib12) 2019; 6736 Francisco, Sage, Sharpe (bib5) 2010; 236 Paz-Ares, Luft, Vicente (bib14) 2018; 379 Roach, Zhang, Corigliano (bib16) 2016; 24 Greenwald, Freeman, Sharpe (bib9) 2005; 23 Socinski, Jotte, Cappuzzo (bib15) 2018; 378 Haratani, Hayashi, Chiba (bib20) 2018; 4 Pavan, Calvetti, Maso (bib25) 2019; 24 Reck, Rodríguez-Abreu, Robinson (bib11) 2016; 375 Freeman, Long, Iwai (bib10) 2000; 192 Iwai, Ishida, Tanaka, Okazaki, Honjo, Minato (bib8) 2002; 99 Brahmer, Reckamp, Baas (bib2) 2015; 373 Pardoll (bib6) 2012; 12 Teraoka, Fujimoto, Morimoto (bib21) 2017; 12 Sato, Akamatsu, Murakami (bib22) 2018; 115 Borghaei, Paz-Ares, Horn (bib1) 2015; 373 Rittmeyer, Barlesi, Waterkamp (bib4) 2017; 389 Eisenhauer, Therasse, Bogaerts (bib17) 2009; 45 Herbst, Baas, Kim (bib3) 2016; 387 Ksienski, Wai, Croteau (bib23) 2019; 20 Gandhi, Rodríguez-Abreu, Gadgeel (bib13) 2018; 378 Huang, Postow, Orlowski (bib19) 2017; 545 Reck, Rodríguez-Abreu, Robinson (bib18) 2019; 37 Kenmotsu, Sakai, Kato (bib24) 2017; 35 Dong, Strome, Salomao (bib7) 2002; 8 Pardoll (10.1016/j.cllc.2020.02.017_bib6) 2012; 12 Brahmer (10.1016/j.cllc.2020.02.017_bib2) 2015; 373 Huang (10.1016/j.cllc.2020.02.017_bib19) 2017; 545 Gandhi (10.1016/j.cllc.2020.02.017_bib13) 2018; 378 Teraoka (10.1016/j.cllc.2020.02.017_bib21) 2017; 12 Socinski (10.1016/j.cllc.2020.02.017_bib15) 2018; 378 Dong (10.1016/j.cllc.2020.02.017_bib7) 2002; 8 Ksienski (10.1016/j.cllc.2020.02.017_bib23) 2019; 20 Kenmotsu (10.1016/j.cllc.2020.02.017_bib24) 2017; 35 Freeman (10.1016/j.cllc.2020.02.017_bib10) 2000; 192 Paz-Ares (10.1016/j.cllc.2020.02.017_bib14) 2018; 379 Borghaei (10.1016/j.cllc.2020.02.017_bib1) 2015; 373 Sato (10.1016/j.cllc.2020.02.017_bib22) 2018; 115 Reck (10.1016/j.cllc.2020.02.017_bib11) 2016; 375 Herbst (10.1016/j.cllc.2020.02.017_bib3) 2016; 387 Eisenhauer (10.1016/j.cllc.2020.02.017_bib17) 2009; 45 Pavan (10.1016/j.cllc.2020.02.017_bib25) 2019; 24 Greenwald (10.1016/j.cllc.2020.02.017_bib9) 2005; 23 Mok (10.1016/j.cllc.2020.02.017_bib12) 2019; 6736 Reck (10.1016/j.cllc.2020.02.017_bib18) 2019; 37 Roach (10.1016/j.cllc.2020.02.017_bib16) 2016; 24 Francisco (10.1016/j.cllc.2020.02.017_bib5) 2010; 236 Haratani (10.1016/j.cllc.2020.02.017_bib20) 2018; 4 Rittmeyer (10.1016/j.cllc.2020.02.017_bib4) 2017; 389 Iwai (10.1016/j.cllc.2020.02.017_bib8) 2002; 99 |
References_xml | – volume: 4 start-page: 374 year: 2018 end-page: 378 ident: bib20 article-title: Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer publication-title: JAMA Oncol contributor: fullname: Chiba – volume: 45 start-page: 228 year: 2009 end-page: 247 ident: bib17 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer contributor: fullname: Bogaerts – volume: 24 start-page: 1128 year: 2019 end-page: 1136 ident: bib25 article-title: Peripheral blood markers identify risk of immune-related toxicity in advanced non–small cell lung cancer treated with immune-checkpoint inhibitors publication-title: Oncologist contributor: fullname: Maso – volume: 389 start-page: 255 year: 2017 end-page: 265 ident: bib4 article-title: Atezolizumab versus docetaxel in patients with previously treated non–small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial publication-title: Lancet contributor: fullname: Waterkamp – volume: 373 start-page: 123 year: 2015 end-page: 135 ident: bib2 article-title: Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer publication-title: N Engl J Med contributor: fullname: Baas – volume: 378 start-page: 2078 year: 2018 end-page: 2092 ident: bib13 article-title: Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer publication-title: N Engl J Med contributor: fullname: Gadgeel – volume: 23 start-page: 515 year: 2005 end-page: 548 ident: bib9 article-title: The B7 family revisited publication-title: Annu Rev Immunol contributor: fullname: Sharpe – volume: 236 start-page: 219 year: 2010 end-page: 242 ident: bib5 article-title: The PD-1 pathway in tolerance and autoimmunity publication-title: Immunol Rev contributor: fullname: Sharpe – volume: 8 start-page: 793 year: 2002 end-page: 800 ident: bib7 article-title: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion publication-title: Nat Med contributor: fullname: Salomao – volume: 545 start-page: 60 year: 2017 end-page: 65 ident: bib19 article-title: T-cell invigoration to tumour burden ratio associated with anti–PD-1 response publication-title: Nature contributor: fullname: Orlowski – volume: 35 year: 2017 ident: bib24 article-title: Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non–small cell lung cancer: a study on risk factors using interim results of post-marketing all-case surveillance publication-title: J Clin Oncol contributor: fullname: Kato – volume: 12 start-page: 252 year: 2012 end-page: 264 ident: bib6 article-title: The blockade of immune checkpoints in cancer immunotherapy publication-title: Nat Rev Cancer contributor: fullname: Pardoll – volume: 12 start-page: 1798 year: 2017 end-page: 1805 ident: bib21 article-title: Early immune-related adverse events and association with outcome in advanced non–small cell lung cancer patients treated with nivolumab: a prospective cohort study publication-title: J Thorac Oncol contributor: fullname: Morimoto – volume: 24 start-page: 392 year: 2016 end-page: 397 ident: bib16 article-title: Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non–small-cell lung cancer publication-title: Appl Immunohistochem Mol Morphol contributor: fullname: Corigliano – volume: 20 start-page: e97 year: 2019 end-page: e106 ident: bib23 article-title: Efficacy of nivolumab and pembrolizumab in patients with advanced non–small-cell lung cancer needing treatment interruption because of adverse events: a retrospective multicenter analysis publication-title: Clin Lung Cancer contributor: fullname: Croteau – volume: 379 start-page: 2040 year: 2018 end-page: 2051 ident: bib14 article-title: Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer publication-title: N Engl J Med contributor: fullname: Vicente – volume: 6736 start-page: 1 year: 2019 end-page: 12 ident: bib12 article-title: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non–small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial publication-title: Lancet contributor: fullname: Kudaba – volume: 387 start-page: 1540 year: 2016 end-page: 1550 ident: bib3 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1–positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial publication-title: Lancet contributor: fullname: Kim – volume: 378 start-page: 2288 year: 2018 end-page: 2301 ident: bib15 article-title: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC publication-title: N Engl J Med contributor: fullname: Cappuzzo – volume: 192 start-page: 1027 year: 2000 end-page: 1034 ident: bib10 article-title: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation publication-title: J Exp Med contributor: fullname: Iwai – volume: 99 start-page: 12293 year: 2002 end-page: 12297 ident: bib8 article-title: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade publication-title: Proc Natl Acad Sci U S A contributor: fullname: Minato – volume: 375 start-page: 1823 year: 2016 end-page: 1833 ident: bib11 article-title: Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer publication-title: N Engl J Med contributor: fullname: Robinson – volume: 373 start-page: 1627 year: 2015 end-page: 1639 ident: bib1 article-title: Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer publication-title: N Engl J Med contributor: fullname: Horn – volume: 115 start-page: 71 year: 2018 end-page: 74 ident: bib22 article-title: Correlation between immune-related adverse events and efficacy in non–small cell lung cancer treated with nivolumab publication-title: Lung Cancer contributor: fullname: Murakami – volume: 37 start-page: 537 year: 2019 end-page: 546 ident: bib18 article-title: Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-l1 tumor proportion score of 50% or greater publication-title: J Clin Oncol contributor: fullname: Robinson – volume: 24 start-page: 392 year: 2016 ident: 10.1016/j.cllc.2020.02.017_bib16 article-title: Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non–small-cell lung cancer publication-title: Appl Immunohistochem Mol Morphol doi: 10.1097/PAI.0000000000000408 contributor: fullname: Roach – volume: 37 start-page: 537 year: 2019 ident: 10.1016/j.cllc.2020.02.017_bib18 article-title: Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-l1 tumor proportion score of 50% or greater publication-title: J Clin Oncol doi: 10.1200/JCO.18.00149 contributor: fullname: Reck – volume: 4 start-page: 374 year: 2018 ident: 10.1016/j.cllc.2020.02.017_bib20 article-title: Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.2925 contributor: fullname: Haratani – volume: 378 start-page: 2288 year: 2018 ident: 10.1016/j.cllc.2020.02.017_bib15 article-title: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC publication-title: N Engl J Med doi: 10.1056/NEJMoa1716948 contributor: fullname: Socinski – volume: 115 start-page: 71 year: 2018 ident: 10.1016/j.cllc.2020.02.017_bib22 article-title: Correlation between immune-related adverse events and efficacy in non–small cell lung cancer treated with nivolumab publication-title: Lung Cancer doi: 10.1016/j.lungcan.2017.11.019 contributor: fullname: Sato – volume: 373 start-page: 1627 year: 2015 ident: 10.1016/j.cllc.2020.02.017_bib1 article-title: Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1507643 contributor: fullname: Borghaei – volume: 12 start-page: 252 year: 2012 ident: 10.1016/j.cllc.2020.02.017_bib6 article-title: The blockade of immune checkpoints in cancer immunotherapy publication-title: Nat Rev Cancer doi: 10.1038/nrc3239 contributor: fullname: Pardoll – volume: 23 start-page: 515 year: 2005 ident: 10.1016/j.cllc.2020.02.017_bib9 article-title: The B7 family revisited publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.23.021704.115611 contributor: fullname: Greenwald – volume: 35 issue: Suppl 15 year: 2017 ident: 10.1016/j.cllc.2020.02.017_bib24 article-title: Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non–small cell lung cancer: a study on risk factors using interim results of post-marketing all-case surveillance publication-title: J Clin Oncol contributor: fullname: Kenmotsu – volume: 387 start-page: 1540 year: 2016 ident: 10.1016/j.cllc.2020.02.017_bib3 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1–positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(15)01281-7 contributor: fullname: Herbst – volume: 12 start-page: 1798 year: 2017 ident: 10.1016/j.cllc.2020.02.017_bib21 article-title: Early immune-related adverse events and association with outcome in advanced non–small cell lung cancer patients treated with nivolumab: a prospective cohort study publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2017.08.022 contributor: fullname: Teraoka – volume: 375 start-page: 1823 year: 2016 ident: 10.1016/j.cllc.2020.02.017_bib11 article-title: Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1606774 contributor: fullname: Reck – volume: 389 start-page: 255 year: 2017 ident: 10.1016/j.cllc.2020.02.017_bib4 article-title: Atezolizumab versus docetaxel in patients with previously treated non–small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32517-X contributor: fullname: Rittmeyer – volume: 24 start-page: 1128 year: 2019 ident: 10.1016/j.cllc.2020.02.017_bib25 article-title: Peripheral blood markers identify risk of immune-related toxicity in advanced non–small cell lung cancer treated with immune-checkpoint inhibitors publication-title: Oncologist doi: 10.1634/theoncologist.2018-0563 contributor: fullname: Pavan – volume: 378 start-page: 2078 year: 2018 ident: 10.1016/j.cllc.2020.02.017_bib13 article-title: Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1801005 contributor: fullname: Gandhi – volume: 8 start-page: 793 year: 2002 ident: 10.1016/j.cllc.2020.02.017_bib7 article-title: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion publication-title: Nat Med doi: 10.1038/nm730 contributor: fullname: Dong – volume: 99 start-page: 12293 year: 2002 ident: 10.1016/j.cllc.2020.02.017_bib8 article-title: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.192461099 contributor: fullname: Iwai – volume: 20 start-page: e97 year: 2019 ident: 10.1016/j.cllc.2020.02.017_bib23 article-title: Efficacy of nivolumab and pembrolizumab in patients with advanced non–small-cell lung cancer needing treatment interruption because of adverse events: a retrospective multicenter analysis publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2018.09.005 contributor: fullname: Ksienski – volume: 192 start-page: 1027 year: 2000 ident: 10.1016/j.cllc.2020.02.017_bib10 article-title: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation publication-title: J Exp Med doi: 10.1084/jem.192.7.1027 contributor: fullname: Freeman – volume: 236 start-page: 219 year: 2010 ident: 10.1016/j.cllc.2020.02.017_bib5 article-title: The PD-1 pathway in tolerance and autoimmunity publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2010.00923.x contributor: fullname: Francisco – volume: 6736 start-page: 1 year: 2019 ident: 10.1016/j.cllc.2020.02.017_bib12 article-title: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non–small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial publication-title: Lancet contributor: fullname: Mok – volume: 379 start-page: 2040 year: 2018 ident: 10.1016/j.cllc.2020.02.017_bib14 article-title: Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1810865 contributor: fullname: Paz-Ares – volume: 373 start-page: 123 year: 2015 ident: 10.1016/j.cllc.2020.02.017_bib2 article-title: Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1504627 contributor: fullname: Brahmer – volume: 545 start-page: 60 year: 2017 ident: 10.1016/j.cllc.2020.02.017_bib19 article-title: T-cell invigoration to tumour burden ratio associated with anti–PD-1 response publication-title: Nature doi: 10.1038/nature22079 contributor: fullname: Huang – volume: 45 start-page: 228 year: 2009 ident: 10.1016/j.cllc.2020.02.017_bib17 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 contributor: fullname: Eisenhauer |
SSID | ssj0026312 |
Score | 2.4107823 |
Snippet | In clinical trials, first-line treatment with pembrolizumab improved overall survival (OS) in patients with advanced non–small-cell lung cancer (NSCLC) with a... In clinical trials, first-line treatment with pembrolizumab improved overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC) with a... BACKGROUNDIn clinical trials, first-line treatment with pembrolizumab improved overall survival (OS) in patients with advanced non-small-cell lung cancer... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | e366 |
SubjectTerms | First-line pembrolizumab Immune checkpoint inhibitor Immune-related adverse events Real-world data Tumor proportion score of more than 50 |
Title | Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non–Small-Cell Lung Cancer and High PD-L1 Tumor Expression |
URI | https://dx.doi.org/10.1016/j.cllc.2020.02.017 https://www.ncbi.nlm.nih.gov/pubmed/32199806 https://search.proquest.com/docview/2381846181 |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF4SB0ovpe-6bcIUeiuq9Vg99mgcG7dOjXESktuyu9olKrIUHBuSHEL_Q_5hf0lnpVWg0PbQi4SEFi07o5lvtN_MEPIxU1mswjzzpJ9KjyYy9oTAg1aB0b5kRoum2uc8mZ7Sr-fx-Q4ZdbkwllbpbH9r0xtr7e4M3GoOLoticGw796Q2GvejRvV2yR66I0p7ZG_4ZTadP8RdSdRuesa2cysOcLkzLc1LlaWtZBj6TenOpm_ZH_3T3_Bn44cmT8kTByBh2M7xGdnR1XPy6JvbIn9B7pcI_byGIwNjWx9CqBuoDUwKxHkehp4aFnolbbOe2-1KSCgqWLTFVa_grNhcwNDRAqBew9L-jrcFnGBeVz9_3B-vRFl6I12WcIRmAkb2yTWIKgfLGIHFoXcUwMl2hWPH145kW70kp5PxyWjquc4LnqIZ3WBQaZhMBdOhz_IczSGNjc4yTREe6DyK0aMxNJVai9SECcsZM4kKqNTMBExJP3pFelVd6TcEFLM2QZkkFIomAhUh0giVTWQyDP3itE8-devNL9sCG7xjnn3nVjrcSof7IUfp9EnciYT_piYcPcA_x33o5Mfx-7GbIqLS9faKN5CFJgh0-uR1K9iHeUShzUD0k7f_-dZ35LG9ailp70lvs97qfcQwG3lAdj_fBQdOU-15tjyb_QJv8vKu |
link.rule.ids | 315,786,790,4521,24144,27957,27958,45620,45714 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaWrgRcEG_Kc5C4oah52El8rEqrLtutqt2u2JtlO7YISpNVt5WAE_9h_yG_hHHirIQEHLjkkMRK5Jl88038eYaQd7nOmY6LPFBhpgKaKhZIiQejI2tCxa2RbbXPZTo_px8v2MUBmfR7YZys0mN_h-ktWvszIz-bo8uyHJ25zj2Zy8bDpHW9W-SQsiyiA3I4PjqeL2_yrjTpFj2Z69yKA_zemU7mpavKVTKMw7Z0Z9u37I_x6W_8s41Ds_vknieQMO7e8QE5MPVDcvvEL5E_ItenSP2CViMDU1cfQupv0FiYlcjzAkw9DazMRrlmPd_3G6mgrGHVFVe9gk_l7jOMvSwAmi2cut_xroATLJv654_rs42sqmBiqgoWCBMwcXduQdYFOMUIrD4EiwjW-w2OnX71Itv6MTmfTdeTeeA7LwSa5nSHSaXlKpPcxCEvCoRDyqzJc0ORHpgiYRjROEKlMTKzccoLzm2qI6oMtxHXKkyekEHd1OYZAc0dJmibxlLTVKIjJAapsk1sjqkfy4bkfT_f4rIrsCF65dkX4awjnHVEGAu0zpCw3iTiNzcRGAH-Oe5tbz-B349bFJG1afZXoqUsNEWiMyRPO8PevEcSux2IYfr8P5_6htyZr08WYnG0PH5B7rornTztJRnstnvzCvnMTr32_voLsaXy_Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-World+Efficacy+of+First-Line+Pembrolizumab+in+Patients+With+Advanced+or+Recurrent+Non%E2%80%93Small-Cell+Lung+Cancer+and+High+PD-L1+Tumor+Expression&rft.jtitle=Clinical+lung+cancer&rft.au=Tambo%2C+Yuichi&rft.au=Sone%2C+Takashi&rft.au=Shibata%2C+Kazuhiko&rft.au=Nishi%2C+Kouichi&rft.date=2020-09-01&rft.pub=Elsevier+Inc&rft.issn=1525-7304&rft.eissn=1938-0690&rft.volume=21&rft.issue=5&rft.spage=e366&rft.epage=e379&rft_id=info:doi/10.1016%2Fj.cllc.2020.02.017&rft.externalDocID=S1525730420300425 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1525-7304&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1525-7304&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1525-7304&client=summon |